Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab

Targeted therapies aiming at oncogenic aberrations and immunotherapies has transformed treatment strategies in NSCLC. Patients harboring EGFR mutations, ROS1 rearrangements or ALK positive lung cancer could benefit from tyrosine kinase inhibitors (TKIs) in terms of response and survival [1 –3]. Immunotherapies, typicalized by immune checkpoint inhibitors (ICIs) that target programmed cell death protein 1 (PD-1) and its ligand (PD-L1), could elicit durable antitumor responses in NSCLC [4–6]. Unfortunately, only a subgroup of patients could derive clinical benefit, suggesting the ur gent need to develop novel biomarkers and treatment, which would further enhance therapeutic benefit.

Source: Lung Cancer - February 17, 2021 Category: Cancer & Oncology Authors: Xiaoling Shang, Zhenxiang Li, Jian Sun, Chenglong Zhao, Jiamao Lin, Haiyong Wang Source Type: research